Incyte Corporation

Incyte Holdings Corporation

Bristol-myers Squibb Pharma Company

Rib-x Pharmaceuticals, Inc.

Melinta Therapeutics, Inc.

Bristol-myers Squibb Compnay

Dupont Pharmaceuticals Company

Other

Incyte Incorporation

Inctye Holdings Corporation

Jiacheng Zhou

Zhongjiang Jia

Yongchun Pan

Pingli Liu

Shili Chen

David J Meloni

Yongzhong Wu

Lei Qiao

Qun Li

Michael Xia

Rongliang Lou

Philip Ma

Joseph M Salvino

Mei Li

Deping Wang

Hui-Yin Li

Ganfeng Cao

Adegboyega K Oyelere

Brian Walter Metcalf

Jay J Farmer

Bo Shen

Ashoke Bhattacharjee

Pasquale N Confalone

Jennifer N Tran

James David Rodgers

Haisheng Wang

Ming Tao

Andrew Paul Combs

Eddy W Yue

Richard B Sparks

Wenyu Zhu

Yun-Long Li

Yi Heng Chen

Stacey Shepard

Rajagopal Bakthavatchalam

Christopher A Teleha

Charles G Clark

Luigi Anzalone

Changsheng Zheng

Jung-Hui Sun

Timothy C Burn

Lingkai Weng

Yusheng Wu

Roger Hanselmann

Lynette May Oh

Qiyan Lin

Naijing Su

Tai-Yuen Yue

Yi C Chen

William Frietze

Wayne Han

Joel A Goldberg

Dane M Springer

Alia Orbin

Timothy Martin

Dengjin Wang

Chongsheng Eric Shi

Vaqar Sharief

Jianji Wang

James M Parks

Osama Suleiman

Joseph A Sclafani

Lucius T Rossano

Daniel Carper

Robert Wilson

Weiguo Liu

Mark Wright

Yi Li

Yingrui Dai

David Meloni

Fuqiang Jin

Thomas E Smyser

Phillip C Liu

Aibin Zhang

Anthony J Tomaine

Chris Teleha

Yi Chen

The present invention is related to processes for preparing ruxolitinib, or a salt thereof, and related synthetic intermediates related thereto.

Process and intermediates for preparing a JAK inhibitor

The present application relates to crystalline solid forms of an inhibitor of BET proteins such as BRD2, BRD3, BRD4, and BRD-t, including methods of preparation thereof, and intermediates in the preparation thereof, where the compound is useful in the treatment of diseases such as cancer.

Crystalline solid forms of a BET inhibitor

The present invention is related to processes for preparing itacitinib, or a salt thereof, and related synthetic intermediates related thereto.

Process and intermediates for preparing a JAK1 inhibitor

The present invention is directed to dihydrochloric acid and dibenzenesulfonic acid salts of the c-Met kinase inhibitor 2-fluoro-N-methyl-4-[7-(quinolin-6-ylmethyl)-imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide, and pharmaceutical compositions thereof, useful in the treatment of cancer and other diseases related to the dysregulation of kinase pathways. The present invention further relates to processes and intermediates for preparing 2-fluoro-N-methyl-4-[7-(quinolin-6-ylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide, and salts thereof.

Salts of 2-fluoro-n-methyl-4-[7-(quinolin-6-yl-methyl)-imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide and processes related to preparing the same

This application relates to processes and intermediates for the preparation of the PD-1/PD-L1 inhibitor (R)-1-((7-cyano-2-(3'-((2-(difluoromethyl)-7-((3-hydroxypyrrolidin-1-yl)methyl)pyrido[3,2-d]pyrimidin-4-yl)amino)-2,2′-dimethyl-[1,1′-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)piperidine-4-carboxylic acid, and salts and crystalline forms thereof, where the PD-1/PD-L1 inhibitor and solid forms and salt forms thereof are useful in the treatment of various diseases including infectious diseases and cancer.

Process for making a PD-1/PD-L1 inhibitor and salts and crystalline forms thereof

The present invention is related to processes for preparing a composition comprising an enantiomeric excess of a substituted pyrrolo[2,3-d]pyrimidine utilizing chiral acids.

Process for preparing compositions comprising an enantiomeric excess of a substituted pyrrolo[2,3-d]pyrimidine

The present application provides salt forms of N-(4-(4-Amino-7-(1-isobutyrylpiperidin-4-yl)pyrrolo[1,2-f][1,2,4]triazin-5-yl)phenyl)-1-isopropyl-2,4-dioxo-3-(pyridin-2-yl)-1,2,3,4-tetrahydropyrimidine-5-carboxamide and N-(4-(4-Amino-7-(1-isobutyrylpiperidin-4-yl)pyrrolo[1,2-f][1,2,4]triazin-5-yl)phenyl)-1-isopropyl-2,4-dioxo-3-phenyl-1,2,3,4-tetrahydropyrimidine-5-carboxamide, which are useful as inhibitors of TAM kinases, as well as processes and intermediates related thereto.

Salts of TAM inhibitors

The present invention relates to processes of preparing PD-1/PD-L1 inhibitor (R)-1-((7-cyano-2-(3'-(3-(((R)-3-hydroxypyrrolidin-1-yl)methyl)-1,7-naphthyridin-8-ylamino)-2,2′-dimethylbiphenyl-3-yl)benzo[d]oxazol-5-yl)methyl)pyrrolidine-3-carboxylic acid, or salts thereof, related synthetic intermediates, and salts of the intermediates, where the PD-1/PD-L1 inhibitor is useful in the treatment of various diseases including infectious diseases and cancer.

Process of preparing a PD-1/PD-L1 inhibitor

The present disclosure is related to processes for preparing baricitinib, salts thereof, and related synthetic intermediate compounds and salts thereof.

The present invention relates to salt forms of the Pim kinase inhibitor N-{(7R)-4-[(3R,4R,5S)-3-amino-4-hydroxy-5-methylpiperidin-1-yl]-7-hydroxy-6,7-dihydro-5H-cyclopenta[b]pyridin-3-yl}-6-(2,6-difluorophenyl)-5-fluoropyridine-2-carboxamide, including methods of preparation thereof, and intermediates in the preparation thereof, where the compound is useful in the treatment of Pim kinase-related diseases such as cancer.

Salts of a Pim kinase inhibitor

Crystalline solid forms of a bet inhibitor

The present application provides processes for preparing (R)-4-(3-((S)-1-(4-amino-3-methyl-1H-pyrazolo[3,4-d]pyrimidin-1-yl)ethyl)-5-chloro-2-ethoxy-6-fluorophenyl)pyrrolidin-2-one, which is useful as an inhibitor phosphoinositide 3-kinase-delta (PI3Kδ), as well as a salt form and intermediates related thereto.

Salts and processes of preparing a PI3K inhibitor

The present invention relates to salt forms of the Fibroblast Growth Factor Receptors (FGFR) inhibitor 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-8-(morpholin-4-ylmethyl)-1,3,4,7-tetrahydro-2H-pyrrolo[3',2′:5,6]pyrido[4,3-d]pyrimidin-2-one, including methods of preparation thereof, where the compound is useful in the treatment of FGFR mediated diseases such as cancer.

Salts of an FGFR inhibitor

Growing community of inventors

Newark, DE, United States of America

Jiacheng Zhou